Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Challenges and Opportunities for Respiratory Syncytial Virus Vaccines
Although respiratory syncytial virus (RSV) has been a high priority for vaccine development for over 50 years now, still no vaccine is available and none has yet demonstrated sufficient promise to move to licensure. The success of RSV immune prophylaxis and the availability of ever more powerful tools to study the immune response and pathogenesis of disease, combined with the ability to construct a wide variety of vaccines using different vaccine platforms, give us grounds to believe that an RSV vaccine is within reach. This book brings together in one source what is currently known about the virus: its clinical and epidemiologic features; the host response and pathogenesis of the disease; vaccines, vaccine platforms, and treatment; and animal and tissue culture models of RSV infection. It is designed to organize the critical information relevant to RSV vaccine development, facilitate the assimilation of data, and speed progress toward producing a safe and effective vaccine.
Challenges and Opportunities for Respiratory Syncytial Virus Vaccines
Although respiratory syncytial virus (RSV) has been a high priority for vaccine development for over 50 years now, still no vaccine is available and none has yet demonstrated sufficient promise to move to licensure. The success of RSV immune prophylaxis and the availability of ever more powerful tools to study the immune response and pathogenesis of disease, combined with the ability to construct a wide variety of vaccines using different vaccine platforms, give us grounds to believe that an RSV vaccine is within reach. This book brings together in one source what is currently known about the virus: its clinical and epidemiologic features; the host response and pathogenesis of the disease; vaccines, vaccine platforms, and treatment; and animal and tissue culture models of RSV infection. It is designed to organize the critical information relevant to RSV vaccine development, facilitate the assimilation of data, and speed progress toward producing a safe and effective vaccine.
The Immune Response to Infection
Examines the mechanisms of both the innate and adaptive immune systems as they relate to infection and disease. • Explores the underlying mechanisms of immunity and the many sequelae of host-pathogen interactions, ranging from the sterile eradication of the invader, to controlled chronic infection, to pathologic corollaries of the host-pathogen crosstalk. • Discusses the pathogenesis of certain autoimmune disorders and cancers that are induced by infectious agents but then become independent of the infection process. • Serves as a resource for immunologists, molecular microbiologists, infectious disease clinicians, researchers, and students.
MERS-CoV
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which potentially utilized palm civets as its intermediate hosts, MERS-CoV likely transmits to humans through dromedary camels. Animal models, such as humanized mice and nonhuman primates, have been developed for studying MERS-CoV infection. Currently, there are no vaccines and therapeutics approved for the prevention and treatment of MERS-CoV infection...
NIAID AIDS Agenda
None
Adverse reactions to HIV vaccines : medical, ethical, and legal issues.
AIDS researchers are investigating new vaccines that would prevent infection with HIV and reduce the spread of AIDS. Some have argued that product liability concerns have discouraged investment in HIV vaccine research and development. The purpose of this OTA background paper is to describe the current state of development of HIV vaccines, and to discuss what is known about adverse reactions that may occur. The background paper provides an overview of ethical issues that arise in the conduct of HIV vaccine trials. The report also discusses alternatives to the current product liability system to encourage the development of HIV vaccines and to fairly compensate those who are harmed as a result of adverse reactions to the vaccine. This background paper was prepared in response to a request from the Subcommittee on Health of the House Ways and Means Committee. It is eleventh in OTA's series of studies on HIV-related issues.
Burger's Medicinal Chemistry, Drug Discovery and Development, 8 Volume Set
Burger’s Medicinal Chemistry, Drug Discovery and Development Explore the freshly updated flagship reference for medicinal chemists and pharmaceutical professionals The newly revised eighth edition of the eight-volume Burger’s Medicinal Chemistry, Drug Discovery and Development is the latest installment in this celebrated series covering the entirety of the drug development and discovery process. With the addition of expert editors in each subject area, this eight-volume set adds 35 chapters to the extensive existing chapters. New additions include analyses of opioid addiction treatments, antibody and gene therapy for cancer, blood-brain barrier, HIV treatments, and industrial-academic co...
The Natural Health Guide to Beating Supergerms
Once easily cured by antibiotics, "supergerms" have returned, now resistant to many over-prescribed drugs. This volume details the causes of this significant problem and shows readers how to rely on natural means to protect themselves from deadly diseases.
Community-Acquired Pneumonia
Pneumonia (along with influenza) is the sixth leading cause of death in adults. About 4 million adults develop pneumonia each year in the US, resulting in 64 million days of restricted activity, 39 million days of bed confinement, and 10 million days of lost work. Yet the admission rates to hospital, length of stay, investigations, antimicrobial therapy and prevention strategies vary greatly from one geographic area to the next, and the scientific basis for many of our management strategies for pneumonia is weak to nonexistent. There are over 100 microbial agents that can cause pneumonia and many of these, especially Streptococcus pneumoniae, Group A streptococcus, and Staphylococcus aureus, are in a state of flux in terms of changing antimicrobial resistance. This book is designed to provide new information about pneumonia and identify critical research questions that will come to the fore as we enter the 21st century.
